论文部分内容阅读
[目的]探讨芳香化酶P450Arom与卵巢浆液性腺癌的相关性及对患者预后的影响。[方法]采用免疫组织化学方法检测57例卵巢浆液性腺癌标本中P450Arom的表达,并分析其与患者临床病理特征及预后的相关性。[结果]57例卵巢浆液性腺癌组织中P450Arom阳性率为61.40%,不同分期以及不同分级的患者之间表达有差异(P=0.016;P=0.000),肿瘤分期越高、分化越差,P450Arom表达阳性率越高。P450Arom阳性表达患者预后差,P450Arom表达状况与患者年龄无关(P>0.05)。Cox多因素回归分析显示卵巢浆液性腺癌中P450Arom表达可增加患者死亡风险。[结论]卵巢浆液性腺癌组织中存在P450Arom表达,且与患者的预后差可能相关,可为芳香化酶抑制剂在卵巢浆液性腺癌上的应用提供一定参考依据。
[Objective] To explore the correlation between aromatase P450Arom and ovarian serous adenocarcinoma and its effect on the prognosis of patients. [Method] The expression of P450Arom in 57 specimens of ovarian serous adenocarcinoma was detected by immunohistochemistry, and its correlation with clinicopathological features and prognosis was analyzed. [Results] The positive rate of P450Arom in 57 cases of ovarian serous adenocarcinoma was 61.40%. There were significant differences in the expression of P450Arom in different stage and different grades (P = 0.016; P = 0.000). The higher the tumor stage, the worse the differentiation, the P450Arom The higher the positive rate of expression. The prognosis of patients with positive P450Arom expression was poor, and the expression of P450Arom had no relation with patient’s age (P> 0.05). Cox multivariate regression analysis showed that P450Arom expression in ovarian serous adenocarcinoma increased the risk of death. [Conclusion] The expression of P450Arom in ovarian serous adenocarcinoma tissue may be correlated with the poor prognosis of patients, which may provide a reference for the application of aromatase inhibitors in ovarian serous adenocarcinoma.